Brainsway stock maintains Buy rating at H.C. Wainwright after strategic investments

Brainsway (NASDAQ:BWAY) reported strong Q2 2025 results, including record net revenue of $12.6 million and $0.05 EPS, alongside a 35% increase in Deep TMS system shipments. The medical device company also announced two strategic investments: an initial $2.3 million equity financing in Axis Management Company and a $5 million convertible loan in Neurolief Ltd., aiming to expand into at-home mental health therapies and accelerate revenue. These developments, supported by Brainsway's strong cash position and 61% YTD stock performance, led H.C. Wainwright to reiterate its Buy rating and raise its price target to $17, underscoring the company's strategic growth and financial strength.

Analysis

Brainsway Ltd. (NASDAQ:BWAY) has demonstrated robust operational and financial performance, reporting record Q2 2025 net revenue of $12.6 million and net earnings of $0.05 per share. This was driven by a 35% year-over-year increase in Deep TMS system shipments, expanding its installed base to 1,522 units and contributing to the stock's 61% year-to-date return. The company is leveraging its strong cash position of $78.3 million to pursue a dual-pronged growth strategy through two key investments. The first is an initial $2.3 million equity financing in Axis Management Company, aimed at accelerating revenue through Axis's network of mental health clinics. The second is a $5 million convertible loan to Neurolief Ltd., which provides an entry into the at-home mental health therapy market and includes an option to acquire the company. These strategic moves have been endorsed by H.C. Wainwright, which reiterated its Buy rating and increased its 12-month price target to $17, citing the value-additive nature of both expanding Brainsway's revenue channels and its technology platform.

Key Decisions for Investors

• Given the strong Q2 earnings, accelerating system placements, and a clear strategic growth path through recent investments, investors with an appetite for growth in the medical device sector could view the current momentum as a positive signal.
• It is crucial to monitor the execution of the new strategic investments, particularly tracking revenue synergies from the Axis partnership and any developments regarding the potential acquisition of Neurolief to validate the long-term growth thesis.
• Considering the stock is trading near its 52-week high after a significant 61% YTD rally, prospective investors should carefully evaluate the valuation against the $17 analyst price target and assess the risk-reward of entering a position at current levels.